Company Encyclopedia
View More
name
Takeda Pharmaceutical Co. Ltd.
4502.JP
News
View More

Innovent, Takeda Close $11.4 Bln Collaboration To Advance Next-Generation IO And ADC Therapies

Innovent Biologics and Takeda have finalized a $11.4 billion global strategic collaboration to advance next-generation immuno-oncology and antibody-drug conjugate therapies. The partnership includes co-development and commercialization of IBI363 in the U.S., with Takeda holding exclusive rights outside Greater China. Takeda also gains rights to IBI343 and an option for IBI3001. Innovent receives a $1.2 billion upfront payment, potential milestone payments, and royalties, with shared profits for IBI363 in the U.S.

rttnews·
4502
0.00%
HK
01801
-1.66%
rttnews·
4502
0.00%
HK
01801
-1.66%

Innovent Biologics partners with Takeda for new therapies; global collaboration effective after satisfying conditions.

Innovent Biologics, a company listed on the Hong Kong Stock Exchange under the ticker symbol 01801, recently revealed that their partnership with Takeda, a multinational pharmaceutical company listed on both the Tokyo Stock Exchange under the symbol 4502 and the New York Stock Exchange under the symbol TAK, has been finalized. The collaboration has officially commenced after meeting all the necessary requirements for closure.

Unusual Whales·
4502
0.00%
HK
01801
-1.66%
Unusual Whales·
4502
0.00%
HK
01801
-1.66%

Takeda Invests $100 Million in Innovent Through Equity Subscription

Takeda Pharmaceutical Co. Ltd. has formed a strategic partnership with Innovent Biologics, including a $100 million equity investment. Takeda will pay Innovent $1.2 billion upfront by March 31, 2026. This deal is reflected in Takeda's revised forecast announced on October 30, 2025. The news was generated by Public Technologies using AI and is for informational purposes only.

Reuters·
4502
0.00%
Reuters·
4502
0.00%

Innovent Biologics Closes Strategic Partnership with Takeda

Innovent Biologics has closed a global strategic partnership with Takeda, fulfilling their License, Option, and Collaboration Agreement, and Share Issuance Agreement. This led to the issuance of 6,913,834 shares, raising approximately HK$778 million. The partnership enhances Innovent's strategic positioning and financial resources for developing biologic medicines. The latest analyst rating for Innovent's stock (HK:1801) is a Hold with a HK$101.00 price target. Innovent Biologics focuses on innovative therapies in the pharmaceutical industry.

Tip Ranks·
HK
01801
-1.66%
4502
0.00%
Tip Ranks·
HK
01801
-1.66%
4502
0.00%

Officer Platford Files To Sell 58,421 Of Takeda Pharmaceutical Co Ltd [TAK]

Officer Platford Giles Richard of Takeda Pharmaceutical Co Ltd filed a Form 144 with the SEC to sell 58,421 restricted shares on December 4, 2025. The sale will be conducted through Interactive Brokers LLC. Form 144 is required for selling restricted stock, allowing sales within 90 days of filing. The Washington Service offers insider trading analysis and data services.

Reuters·
4502
0.00%
Reuters·
4502
0.00%
Posts
View More

Recursion Pharmaceuticals (RXRX) $Recursion Pharmaceuticals(RXRX.US) In-depth Research Report: From Phenotypic Screening to Vertical Integration—Revaluation After Exscientia Acquisition and the New Pa......

  • 0
© 2025 Longbridge｜Disclaimer